GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calliditas Therapeutics AB (NAS:CALT) » Definitions » Accounts Receivable

Calliditas Therapeutics AB (Calliditas Therapeutics AB) Accounts Receivable : $17.64 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Calliditas Therapeutics AB Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Calliditas Therapeutics AB's accounts receivables for the quarter that ended in Dec. 2023 was $17.64 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Calliditas Therapeutics AB's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 36.55.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Calliditas Therapeutics AB's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-1.47.


Calliditas Therapeutics AB Accounts Receivable Historical Data

The historical data trend for Calliditas Therapeutics AB's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calliditas Therapeutics AB Accounts Receivable Chart

Calliditas Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only 4.94 - - 7.58 17.64

Calliditas Therapeutics AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.21 7.58 13.59 11.78 17.64

Calliditas Therapeutics AB Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Calliditas Therapeutics AB Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Calliditas Therapeutics AB's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=17.635/44.022*91
=36.55

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Calliditas Therapeutics AB's accounts receivable are only considered to be worth 75% of book value:

Calliditas Therapeutics AB's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(94.928+0.75 * 17.635+0.5 * 1.991-148.616
-0-0)/26.836
=-1.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Calliditas Therapeutics AB Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Calliditas Therapeutics AB's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Calliditas Therapeutics AB (Calliditas Therapeutics AB) Business Description

Traded in Other Exchanges
Address
Kungsbron 1, D5, Stockholm, SWE, SE-111 22
Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.